Sustained positive clinical results for autologous anti-CD19 #CARTCells in patients with moderate-to-severe generalized myasthenia gravis (Phase II trial).

In vivo CAR-T race for autoimmune grows as two RNA startups enter the clinic Two new startups have begun testing their in vivo CAR-T therapies for autoimmune disease in people: Hangzhou, China-based Immorna, and Massachusetts-based Orna Therapeutics, which Eli Lilly is buying.

In vivo #CARTCells race for autoimmune grows as two RNA startups enter the clinic.

buff.ly/6Vwaz1N

Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform | Cellectis Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer.

Very encouraging interim data for allogeneic, off-the-shelf CAR-T (healthy donor T cells) cema-cel in 24 patients as first-line consolidation in LBCL.
Licensed by Celgene to Servier, then sublicensed to Allogene.

buff.ly/ETu4rW1

The turning point for rare diseases, which affect >300 million people around the world.
A call to get rid of its many structural obstacles, to consider it as molecular surgery unlike drug treatments
gift link:
www.nytimes.com/2026/04/09/o...

John Deering

Weekly reads: 1st FDA-approved CIRM supported therapy, asymmetric histone inheritance, stem cell retraction - The Niche Biologist discusses recent regenerative news including 1st FDA-approved CIRM TX, asymmetric histone inheritance, and skin cell memory.

Weekly #regenerative reads: 1st FDA-approved CIRM supported therapy, asymmetric histone inheritance, stem cell retraction ipscell.com/2026/04/week... #stemcells

tl;dr: NIH is running at about 60% of pre-Trump levels and NSF is running at about 20% of pre-Trump levels of funding-outlays (some directorates far below even that). Utterly catastrophic. An unforced disaster for U.S. society, and the world

Korea establishes first clinical-grade iPSC bank to boost cell therapy R&D Korea establishes first clinical-grade iPSC bank to boost cell therapy R&D

Korea establishes first clinical-grade #iPSCells bank to boost cell therapy R&D.

Join us June 23–24, 2026, Montpellier, for this first‑edition Complex Organoid Systems with Multifaceted InteraCtions Symposium.
Invited speakers :
Katja Wolthers | Amsterdam
Simon Schäfer | Germany
Céline Cougoule | Toulouse
Alexandre Grassart | Lille

#Organoids
buff.ly/wsgMCQg

Gilead puts its Car-T money where its mouth is KITE-753 is to enter pivotal development – head-to-head against Yescarta.

Gilead is testing a bicistronic anti-CD19/CD20 #CAR_T made with a rapid manufacturing method in a Phase III trial vs. Yescarta. Reinventing its own game-changer less than a decade after commercialization.

Marthe Gautier, découvreuse oubliée du chromosome de la trisomie 21 Marthe Gautier est à l’origine de la découverte du chromosome surnuméraire de la trisomie 21, anomalie génétique qui touche 50 000 personnes en France. À l’occasion de la Journée mondiale de la trisom...

Marthe Gautier, découvreuse oubliée du chromosome de la trisomie 21 : l'effet Matilda.
Le Journal du CNRS.
lejournal.cnrs.fr/articles/mar...

Exclusive | Mark Zuckerberg Is Building an AI Agent to Help Him Be CEO The Meta Platforms chief uses the tool to get information faster as the company seeks to embrace artificial intelligence in all it does.

A headline like this would have seemed absurd to me a year ago and it sounds mundane today.

What I see happening at work is so advanced, I just hope someday we either publish outcomes or productize what we’re doing.

Paris said au revoir to cars. Air pollution maps reveal a dramatic change. Air pollution fell substantially as the city restricted car traffic and made way for parks and bike lanes.

“Air pollution fell substantially as Paris restricted car traffic and made way for parks, people-streets and bike-lanes.”

Better for the climate, better for health, better for livability and quality of life.

Common sense.

Such a no-brainer, it’s remarkable that more cities HAVEN’T done the same.

A video shows improvements in hearing in a child who received gene therapy for 𝘖𝘛𝘖𝘍-related deafness. Watch the full video and read the accompanying article: nej.md/4o7ky8f

#MedSky

Enshittification, here we come!

A gene-editing method generates immunotherapeutic CAR T cells in the body @nature.com @j-eyquem.bsky.social @ucsfhealth.bsky.social @ki.se
www.nature.com/articles/d41... @heidiledford.bsky.social
www.nature.com/articles/d41...
www.nature.com/articles/s41...

I Wrote Research Funding Announcements for NIH for 22 Years. This Year They’ve Published 14 How NIH went from 756 funding announcements to 14 in two years — and what it means for every disease that depends on federal research

‼️ We are on track for a staggering 98% reduction in posted NIH funding opportunities this year relative to historical norms. Political review and red tape are blocking approval of funding announcements across the board. See Elizabeth Ginexi’s analysis:

elizabethginexi.substack.com/p/i-wrote-re...

Positive Phase I/II results from Aspen using autologous #iPSCells-derived dopaminergic neuron precursors for surgical treatment of Parkinson’s disease.
Pivoting to phase III.
Very promising!
buff.ly/Z6ItRnM

chocolat!

All three lines are correct and true representations of reality. Data literacy is a crucial skill to make sense of the world.

BioNTech co-founders to exit company and start a new one BioNTech founders Sahin and Türeci to depart by year-end to start new mRNA company; BioNTech to focus on late-stage pipeline and take minority stake in new venture.

BioNTech co-founders to exit company and start a new one
buff.ly/y8vK8nh

Des médecins remettent en cause l'impartialité de la HAS, après un mauvais avis rendu sur une thérapie génique Une thérapie génique, issue d'une découverte française, pouvant soigner deux maladies du sang, a été stoppée en France après un avis défavorable de la Haute autorité de santé (HAS), révèle France…

Pas de CASGEVY en France (CRISPR/Cas9 pour la Bêta Thalassémie et la Drépanocytose)?

Multimillion-dollar gene therapies weren’t supposed to face competition. China has other plans Chinese firm Belief BioMed launches $350K hemophilia B gene therapy, challenging $3.5M Hemgenix by CSL Behring/uniQure, as China leads global race for cheaper gene therapies.

China approved a gene therapy at 1/10 the price of its U.S. rival. China is poised to rapidly disrupt the gene and cell therapy field.

buff.ly/CfZDNgS

First-of-a-kind stem-cell therapies set for approval in Japan Regenerative medicines are headed for people with Parkinson’s disease or severe heart failure — but researchers are concerned about minimal clinical-trial data.

Nature comment: two first #iPSCells medicines got conditional approval after treating only 7–8 patients

Smart acceleration or risky precedent?

buff.ly/2PgcKWj

📣 📣 📣 World first!!

Japan’s health ministry has granted a provisional 7-year approval for the commercialization of two regenerative medicine products derived from #iPSCells, aimed at treating ischemic cardiomyopathy and Parkinson’s disease.
buff.ly/nAKKmib

Merci à Nicolas Henin pour ce fil qui vous explique comment changer de Blue en Eurosky

It’s a really weird time in tech. You’re excited at the idea that AI coding agents are making people 20% - 200% more productive but also know the bean counters are asking if that means they can get away with 2%-20% layoffs.

This is also a very good reason to completely abandon American big tech and their utterly corrupt leaders who only want to enrich themselves.

This article gives an overview of 20 European Alternatives to Major US Technology Services.

Europe has had more than enough of this disgusting mafia gang!

Severus detects somatic structural variation and complex rearrangements in cancer genomes using long-read sequencing - Nature Biotechnology Complex structural variations and rearrangements in cancer are identified using long-read sequencing.

Complex structural variations and rearrangements in cancer are identified using long-read sequencing go.nature.com/3R334eH
rdcu.be/e5kOO